Skip to Content
Merck
All Photos(1)

Documents

919381

Sigma-Aldrich

CCW16

≥95%

Synonym(s):

N-Benzyl-2-chloro-N-(4-(4-methoxyphenoxy)phenyl)acetamide, E3 ubiquitin ligase ligand, Ligand for PROTAC® research, RNF4-targeting ligand

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H20ClNO3
CAS Number:
2361138-33-0
Molecular Weight:
381.85
NACRES:
NA.22

ligand

CCW16

Quality Level

100

Assay

≥95%

form

powder

reaction suitability

reagent type: ligand

functional group

amine

storage temp.

2-8°C

SMILES string

COC1=CC=C(OC2=CC=C(N(CC3=CC=CC=C3)C(CCl)=O)C=C2)C=C1

Application

CCW16 is targeting ligand for the E3 ubiquitin ligase RNF4 (RING finger protein 4) and can be used in targeted protein degradation (TPD) research or in the synthesis of protein degraders. Learn more about proteolysis-targeting chimeras (PROTAC degraders) and the building blocks to design them in our Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation.

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Product No.
Description
Pricing

T144

(±)-Thalidomide, ≥98%, powder

N6287

Nutlin-3, ≥98% (HPLC), powder

P0018

Pomalidomide, ≥98% (HPLC)

SML0580

Nutlin-3a, ≥98% (HPLC)

SML1896

VH298, ≥98% (HPLC)

901490

(S,R,S)-AHPC hydrochloride, ≥97%

901487

(S,S,S)-AHPC hydrochloride, ≥97%

901494

N-Methylated pomalidomide, ≥98%

901558

Lenalidomide, ≥95%

911690

C5 Lenalidomide, ≥95%

917974

BocA1V2PF2

917710

A1V1PF2-OEt, ≥95%

917478

BocA1V1PF2, ≥95%

916978

BocA1V2PF1, ≥95%

917222

A1V2PF1-NHEt, ≥95%

916714

A1V2PF2-NHEt, ≥95%

919438

CCW16-C9-BocNH, ≥95%

919470

CCW16-PEG2-butyl-BocNH, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

919454

CCW16-PEG3-BocNH, ≥95%

919403

CCW16-C4-BocNH, 95%

919446

CCW16-PEG1-BocNH

919489

CCW16-C6-PEG3-butyl-BocNH

919411

CCW16-C6-BocNH

Pictograms

Environment
GHS09

Signal Word

Warning

Hazard Statements

H410

Precautionary Statements

P273 - P391 - P501

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Carl C Ward et al.
ACS chemical biology, 14(11), 2430-2440 (2019-05-07)
Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is

Articles

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service